Physician profile
Anthony Phillips
NPI 1780134593
$15,339.23
in general payments reported to CMS, 2019-2025
31 companies · $3,779 in 2025
The $3,779 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,406 · 2022: $3,058 · 2023: $3,438 · 2024: $2,658 · 2025: $3,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,546 · Travel and Lodging: $1,229 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,546.26 |
| Travel and Lodging | $1,229.02 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,244.98 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,826.76 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,484.02 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,365.23 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Intuitive Surgical, INC. | $1,229.02 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $1,026.69 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $923.41 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $837.15 | 2023-2025 | Auvelity |
| Alkermes, INC. | $792.46 | 2021-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $682.17 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $635.67 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $564.24 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $403.85 | 2021-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $351.79 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Neos Therapeutics, LP | $148.25 | 2021-2024 | Adzenys Xr-Odt |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $135.71 | 2022 | |
| Corium, LLC | $134.02 | 2022-2023 | Azstarys |
| Sunovion Pharmaceuticals INC. | $128.57 | 2021 | |
| Indivior INC. | $74.73 | 2021 | |
| Noven Therapeutics, LLC | $64.46 | 2023-2024 | Xelstrym, Secuado |
| Bausch Health US, LLC | $63.99 | 2022-2023 | Aplenzin |
| Eisai INC. | $60.47 | 2021-2022 | |
| Adlon Therapeutics L.P. | $36.36 | 2021 | |
| Abbott Laboratories | $20.04 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.34 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.36 | 2025 | Rejoyn |
| E.R. Squibb & Sons, L.L.C. | $16.15 | 2024 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $15.80 | 2024 | |
| Tris Pharma INC | $13.38 | 2024 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $12.86 | 2021 | |
| Merck Sharp & Dohme LLC | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.